RxDoctor Payments DataLook up a doctor →

Craig Thieling, MD

Interventional Cardiology · Hattiesburg, MSNPI 1952409609

Payments from drug & device makers

$5,268in general payments, 2019–2025

Across 284 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$1K
  • Boston Scientific$1K
  • Novartis$853
  • Inari Medical, Inc.$502
  • Medtronic$219
  • Boehringer Ingelheim$114
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,19399%
  • Gifts$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,268 in reported general payments places this provider in the 25th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,348,632
Medicare patients
2,378
Services billed
10,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban451$356,407
JardianceEmpagliflozin352$281,338
XareltoRivaroxaban312$253,717
EntrestoSacubitril/Valsartan219$195,105
Repatha SureclickEvolocumab116$89,455
FarxigaDapagliflozin Propanediol33$32,286
MultaqDronedarone Hcl32$31,581
Repatha SyringeEvolocumab33$30,140
Ranolazine ErRanolazine400$21,032
Praluent PenAlirocumab36$20,878
BrilintaTicagrelor31$18,594
Metoprolol Succinate913$10,580
Flecainide Acetate198$6,594
Rosuvastatin Calcium660$5,102
Atorvastatin Calcium674$4,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$356,407451 claims
Boehringer IngelheimJardiance$114$281,338352 claims
Johnson & JohnsonXarelto$43$253,717312 claims
NovartisEntresto$853$195,105219 claims
AstraZenecaFarxiga, Brilinta$12$50,88064 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →